Resection of pancreatic cancer, even for attempted cure, is rarely successful. Almost always, the patient dies of recurrent disease, but may well have extended survival as a result ofthe operation. Historically, the mortality ofresection was so high that palliative resection, in the presence of irresectable local invasion or distant metastases was never attempted. However since 1980 it has become clear that pancreatic resection can be performed with mortality well under 10%. Many surgeons can achieve operative mortality less than 5%. In 28 reports, containing over 2,000 patients, the overall operative mortality was 6.9% 1,2 The median (interquartile range) mortality reported by each author was 7.5 (4.5-12) percent. If, as some surgeons believe, resection offers the best form of palliation3, then these impressively low mortality figures lead us to consider the possibility of palliative resection even in the presence ofirresectable local disease or distant metastases. This paper reports a study ofcurrent attitudes amongst British surgeons to palliative resection for pancreatic carcinoma.
recurrent disease, but may well have extended survival as a result ofthe operation. Historically, the mortality ofresection was so high that palliative resection, in the presence of irresectable local invasion or distant metastases was never attempted. However since 1980 it has become clear that pancreatic resection can be performed with mortality well under 10%. Many surgeons can achieve operative mortality less than 5%. In 28 reports, containing over 2,000 patients, the overall operative mortality was 6.9% 1 In their estimate of the cases in which they had left residual local disease the surgeons reported a median incidence ofresidual disease of 12.5%. The range was from 0-35%, and six (25%) surgeons claimed they had never left macroscopic residual local disease during resection for pancreatic adenocarcinoma.
The responses to the question of whether palliative resection is appropriate are shown in Figure 1 . The initial response of two thirds of the surgeons was that it is never appropriate to perform palliative resection, but when asked specifically to consider local extension, the surgeons were split evenly in their acceptance of the principle of palliative resection. Only three surgeons felt that it could ever be justified to perform pancreatic resection in the similar stage tumours who did not have a resection4, and it is reasonable to suppose that tumour debulking might prolong survival. Palliative resection leaving residual local disease might be considered in conjunction with postoperative adjuvant therapy. Postoperative radiotherapy with 5FU as a radiosensitiser, followed by weekly 5FU, has been shown to increase postoperative survival from 20% to 40% at two years5. A similar regimen produced responses in a significant number ofpatients with irresectable pancreatic cancer6, so it is reasonable to suppose that palliative resection followed by adjuvant therapy could give effective local control in some patients. However there are no published data to support this supposition.
Pancreatectomy for ductal or adenocarcinoma in the presence of liver metastases is rarely undertaken. In addition to the cases mentioned here, Jeekel (Personal Communication) has performed such a resection in three patients. One patient is still alive more than two years after operation. In Mannheim, a small number of combined pancreatic and liver resections have been performed for this type of case, but the outcome is not clear7.
In conclusion it now seems that palliative resection is a feasible option in the management of pancreatic cancer. The exact definition of palliative resection is not clear, because even after so called curative resection the vast majority of patients die of tumour recurrence. The majority of British surgeons do not yet accept the concept of palliative resection to improve symptoms. Evidence of improved quality of life is lacking and studies are urgently needed to evaluate this in patients undergoing surgical and other treatments for pancreatic cancer. Resection for pancreatic carcinoma with liver metastases is accepted only by a small number of surgeons and then only in very carefully selected patients with minimal tumour burden.
Improvements in adjuvant therapy are required, to match improvements already seen in operative mortality, before palliative resection will be widely accepted.
